Yaoyanshe Completed 300 Million Yuan C Round of Financing

On August 16th, the innovative CRO platform Yaoyanshe has completed 300 million yuan C round of financing. This round of financing was jointly led by Eastern bell Capital and Sequoia Capital China, followed by Jingwei China, Yuanhao Capital, and Yuansheng Capital.

"This round of financing will be used for the construction of core barriers, such as technology, supply chain, talent platform, and customer satisfaction construction," said Sun Meilin, the founder of Yaoyanshe.

Founded in December 2015, Yaoyanshe is a technology company providing innovative drug development services for pharmaceutical companies. Based on the talent pool and data, it provides efficient R&D and supply chain services for pharmaceutical companies.

Up to now, Yaoyanshe has provided more than 200 projects for well-known pharmaceutical companies, medical devices companies, and medical institutions at home and abroad. The service covers over 800 research hospitals, and the largest single research project covers more than 300 hospitals.

The decision support system Trial Link, independently developed by Yaoyanshe, can help project management greatly. Trial Link can connect sponsors, institutions, researchers, practitioners, and patients, rebuild the HR model, and provide a balanced choice for pharmaceutical companies. 

Eastern Bell Capital, established in 2010, is an ecosystem-based fund focused on "improving industry efficiency with the supply chain as its core competence". Its focused investment fields include logistics & supply chain, retail & branding, data technology and so on.